Special Issue "Protein Phosphorylation in Cancer: Unraveling the Signaling Pathways"
Deadline for manuscript submissions: 30 November 2020.
Interests: breast cancer; invasion and metastasis; tumor suppressors; tyrosine kinases; signaling networks; phospho-proteomics
The discovery of protein kinase key roles in cancer formation and progression has triggered great interest and stimulated intense research to develop pharmacological kinase inhibitors and therapeutic antibodies. These represent important steps in the development of targeted treatments, but also in the identification of prognostic and predictive biomarkers. Although the majority of efforts have been focused on tyrosine kinase inhibitors (TKI) and tyrosine kinase receptor (RTK)-targeting antibodies, renewed efforts and interests are being directed towards serine/threonine kinases and protein phosphatases.
Unfortunately, inhibitors often lack specificity and affect various kinases. In addition, treated tumors acquire drug resistance and relapse, requiring second-line treatments. With the advent of precision medicine, it is clear that networks are more robust biomarkers than individual proteins and genes. Drug development is moving to dynamic signaling network targeting. In the postgenomic era, post-translational modifications such as protein phosphorylation and how they affect activity or network architecture remain poorly understood. Current advances in (phospho)proteomic profiling allow complex signaling pathways to be unraveled. Bioinformatic modeling makes it possible to deal with the complex interactions between these pathways. It allows uncovering the difficultly discernable signaling cross-talks that positively and negatively affect tumor progression and that generate adaptive chemoresistance. To better cope with the tumor’s complexity, the application of new genetically-engineered and patient-derived xenograft murine models that more accurately mimic the genetic and biological evolution of human cancers makes it possible to design and test new targeted and specific therapeutic strategies.
With this open-access Special Issue on “Protein Phosphorylation in Cancer: Unraveling the Signaling Pathways”, we would like to provide an overview of the recent advances and cutting-edge approaches that allow better studying and understanding kinase/phosphatase signaling in tumor formation, progression, and drug resistance. Both original research articles and comprehensive reviews pertaining to a relevant topic within this vast and complex field are welcome.
We look forward to reading your contributions.
Dr. Peter Coopman
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer development and progression
- protein kinases and phosphatases
- targeted treatments and drug resistance
- biomarker discovery
- signal pathway reconstruction